| Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC (NCT05394233) | Sichuan Cancer Hospital and Research Institute | 2022-06-01 |
| Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer (NCT05517083) | Pusan National University Hospital | 2022-04-01 |
| Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment (NCT06095934) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2022-03-01 |
| Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma (NCT05503667) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-02-01 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408) | Blueprint Medicines Corporation | 2022-01-13 |
| Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) (NCT05598528) | Second Xiangya Hospital of Central South University | 2021-09-28 |
| Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment (NCT04882345) | Shanghai Chest Hospital | 2021-07-15 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (NCT04862780) | Blueprint Medicines Corporation | 2021-06-29 |
| Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations (NCT04695925) | Li Zhang, MD | 2021-03-29 |
| Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients (NCT04512430) | Fundación GECP | 2020-12-02 |
| Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients (NCT04552613) | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 2020-11-23 |
| Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer (NCT04592666) | Fudan University | 2020-10-09 |
| Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma (NCT04201756) | Shanghai Pulmonary Hospital, Shanghai, China | 2020-07-26 |
| Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy (NCT05314296) | N.N. Blokhin National Medical Research Center of Oncology | 2020-06-01 |
| Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib (NCT04358562) | Second Affiliated Hospital of Nanchang University | 2020-05-01 |
| Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (NCT04322890) | Hunan Province Tumor Hospital | 2020-04-16 |
| D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC (NCT04206072) | Betta Pharmaceuticals Co., Ltd. | 2019-12-24 |
| Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer (NCT04085315) | Collin Blakely | 2019-11-12 |
| A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (NCT04042558) | Centre Francois Baclesse | 2019-09-26 |
| Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer (NCT04013542) | M.D. Anderson Cancer Center | 2019-09-13 |
| Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT03909334) | Xiuning Le | 2019-07-25 |
| First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NCT06521034) | Yongchang Zhang | 2019-06-27 |
| 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma (NCT03732352) | Jonsson Comprehensive Cancer Center | 2018-11-28 |
| A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. (NCT03755102) | Memorial Sloan Kettering Cancer Center | 2018-11-21 |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (NCT03653546) | Alpha Biopharma (Jiangsu) Co., Ltd. | 2018-10-29 |
| EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC (NCT03720873) | Fujian Cancer Hospital | 2018-10-01 |
| Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer (NCT03396185) | Betta Pharmaceuticals Co., Ltd. | 2018-05-09 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation (NCT03065387) | M.D. Anderson Cancer Center | 2017-10-31 |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (NCT03175224) | Apollomics Inc. | 2017-09-27 |
| Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer (NCT02947386) | Roswell Park Cancer Institute | 2017-06-29 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 (NCT03049618) | University of Southern California | 2017-03-10 |
| Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC (NCT03046992) | Yuhan Corporation | 2017-02-15 |
| EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism (NCT03002844) | Shanghai Pulmonary Hospital, Shanghai, China | 2016-12-01 |
| Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations (NCT02954523) | Chul Kim | 2016-10-01 |
| EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (NCT02886195) | Fujian Cancer Hospital | 2016-07-01 |
| Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA (NCT02629523) | Chonnam National University Hospital | 2016-06-01 |
| Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy (NCT03042221) | University of Colorado, Denver | 2016-05-10 |
| Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma (NCT03071705) | Instituto Nacional de Cancerologia de Mexico | 2016-03-01 |
| The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib (NCT04640870) | Hellenic Cooperative Oncology Group | 2015-03-15 |
| Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases) (NCT02338011) | Shanghai Chest Hospital | 2014-11-01 |
| Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers (NCT02098954) | Hunan Province Tumor Hospital | 2014-07-01 |
| Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients (NCT03171636) | Hospital Erasto Gaertner | 2014-04-01 |